集群头痛:治疗的最新技术状态
Ildefonso Rodriguez-Leyva1, Maria-Karina Velez-Jimenez2, Silvia García3
1Department of Neurology, Faculty of Medicine, Central Hospital "Dr. Ignacio Morones Prieto," Universidad Autónoma de San Luis Potosi, San Luis Potosi, Mexico.
Frontiers in pain research (Lausanne, Switzerland)
|November 15, 2023
概括
集群头痛 (CH) 治疗方法已经进步,但诊断往往会延迟. 本综述详细介绍了CH的有效过渡性,急性和预防性疗法,包括普雷尼松,三,氧气和维拉帕米尔.
科学领域:
- 神经学 神经学
- 头痛 医学 医学 医学
背景情况:
- 集群头痛 (CH) 是一种严重的自主性头痛障碍.
- 冠状动脉疾病经常被诊断不足,导致治疗延迟和不充分.
- 最近的治疗进步提供了新的管理策略.
研究的目的:
- 对集群头痛 (CH) 的当前治疗选择进行审查.
- 根据美国神经病学会 (AAN) 的证据分类来对治疗进行分类.
- 提供跨越CH的过渡,急性和预防阶段的干预措施的概述.
主要方法:
- 进行了叙事文学评论.
- 搜索了集群头痛的可用治疗方法.
- 利用美国神经病学会 (AAN) 的分类来进行治疗证据.
主要成果:
- 有效和安全的药理和非药理疗法存在于CH.
- 过渡阶段:普雷尼松是最受研究的.
- 急性阶段:三药,氧气和皮肤间的阴道神经刺激是有效的.
- 预防阶段:维拉帕米尔和单克隆抗体是第一线选择.
结论:
- 许多有效和安全的治疗方法可用于偶发性,慢性和耐药性CH.
- 治疗选择应根据个体患者的临床形象进行量身定制.
- 进步提供了在各个阶段管理CH的选择.
相关概念视频
Angle Closure Glaucoma: Treatment
534
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
534
Open Angle Glaucoma: Treatment
459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
216
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
216
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
170
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
170


